Mylan Investors’ Appeal Draws Scrutiny From Second Circuit Panel

Mylan N.V. investors’ attempt to revive class action claims that the pharmaceutical company hid price fixing practices and fraud related to EpiPen rebates received push back from a panel of Second Circuit judges on Thursday, who appeared unreceptive to rationales for overturning a lower court’s ruling during oral arguments.

Shareholders argued that a district court judge erred in tossing the case last year, highlighting alleged misrepresentations around compliance with government rebate rules and collusion with other pharmaceutical companies that manufacture generic drugs.

The US Court of Appeals for the Second Circuit panel appeared ready to uphold Judge J. Paul ...